Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer

被引:10
作者
Sacco, Paola Claudia [1 ]
Maione, Paolo [1 ]
Rossi, Antonio [1 ]
Bareschino, Maria Anna [1 ]
Schettino, Clorinda [1 ]
Guida, Cesare [2 ]
Elmo, Massimo [2 ]
Ambrosio, Rita [1 ]
Barbato, Valentina [1 ]
Zeppa, Rosario [1 ]
Palazzolo, Giovanni [3 ]
Gridelli, Cesare [1 ]
机构
[1] SG Moscati Hosp, Div Med Oncol, Avellino, Italy
[2] SG Moscati Hosp, Div Radiotherapy, Avellino, Italy
[3] USLL5, Cittadella, Italy
关键词
Locally advanced NSCLC; Radiotherapy; Targeted therapy; Chemotherapy; GROWTH-FACTOR RECEPTOR; BLP25 LIPOSOME VACCINE; PHASE-III TRIAL; CLINICAL-TRIALS; SEQUENTIAL CHEMORADIOTHERAPY; INDUCTION CHEMOTHERAPY; TYROSINE KINASE; STAGE-IIIB; ANGIOGENESIS; TUMOR;
D O I
10.1007/s11523-011-0169-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is the most common cancer in the world. One third of patients with non-small cell lung cancer (NSCLC) are diagnosed with locally or regionally advanced unresectable disease at presentation. Currently, in this stage of disease, a combination of chemotherapy and radiotherapy is the standard treatment approach for patients with good performance status, and concomitant chemo-radiotherapy has demonstrated to be the best therapeutic approach. However, despite improvements in treatment, local tumor control remains suboptimal and distant metastases remain the major site of failure. The diversity of molecular abnormalities in NSCLC may partly contribute to its resistance to therapy. It is therefore widely accepted that one approach to improve the efficacy of cancer therapy is the development of rational combinations of anticancer agents that may exhibit synergistic interactions. The introduction of several biologic agents represents an important advance in the management of NSCLC and some of them have shown to have a synergistic effect when given in combination with radiotherapy and chemotherapy in preclinical and in clinical models. In the present review we discuss the rationale and the feasibility of these combinations and the first results available from clinical trials.
引用
收藏
页码:171 / 180
页数:10
相关论文
共 78 条
[51]   The epidermal growth factor receptor as a target for cancer therapy [J].
Mendelsohn, J .
ENDOCRINE-RELATED CANCER, 2001, 8 (01) :3-9
[52]  
Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703
[53]   Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].
Mok, Tony S. ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Yang, Chih-Hsin ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Sunpaweravong, Patrapim ;
Han, Baohui ;
Margono, Benjamin ;
Ichinose, Yukito ;
Nishiwaki, Yutaka ;
Ohe, Yuichiro ;
Yang, Jin-Ji ;
Chewaskulyong, Busyamas ;
Jiang, Haiyi ;
Duffield, Emma L. ;
Watkins, Claire L. ;
Armour, Alison A. ;
Fukuoka, Masahiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957
[54]   Revisions in the International System for Staging Lung Cancer [J].
Mountain, CF .
CHEST, 1997, 111 (06) :1710-1717
[55]  
PEAT N, 1992, CANCER RES, V52, P1954
[56]   Safety and efficacy of darbepoetin alfa in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide [J].
Pirker, Robert ;
Ramlau, Rodryg A. ;
Schuette, Wolfgang ;
Zatloukal, Petr ;
Ferreira, Irene ;
Lillie, Tom ;
Vansteenkiste, Johan F. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) :2342-2349
[57]   Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial [J].
Pirker, Robert ;
Pereira, Jose R. ;
Szczesna, Aleksandra ;
von Pawel, Joachim ;
Krzakowski, Maciej ;
Ramlau, Rodryg ;
Vynnychenko, Ihor ;
Park, Keunchil ;
Yu, Chih-Teng ;
Ganul, Valentyn ;
Roh, Jae-Kyung ;
Bajetta, Emilio ;
O'Byrne, Kenneth ;
de Marinis, Filippo ;
Eberhardt, Wilfried ;
Goddemeier, Thomas ;
Emig, Michael ;
Gatzemeier, Ulrich ;
Pirker, R. ;
Thatcher, N. ;
Armand, J. P. ;
Camus, P. ;
Victor, N. ;
Emig, M. ;
Mueser, M. ;
Pilz, K. ;
Goddemeier, T. ;
Montaner, I. ;
Lachs, Martin ;
Hoang-Sayag, Loan ;
Alvarez, A. ;
Coppola, F. ;
Recondo, G. ;
Richardet, E. ;
Kirsten, F. ;
Karapetis, C. ;
Parente, P. ;
Michael, M. ;
White, S. ;
Boyce, A. ;
Lewis, C. ;
Slancar, M. ;
Pavlakis, N. ;
Abdi, E. ;
Underhill, C. ;
Pittman, K. ;
Burghuber, O. ;
Pirker, R. ;
Ruckser, R. ;
Ulsperger, E. .
LANCET, 2009, 373 (9674) :1525-1531
[58]  
Raben D, 2005, CLIN CANCER RES, V11, P795
[59]   A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer [J].
Ramlau, Rodryg ;
Quoix, Elisabeth ;
Rolski, Janusz ;
Pless, Miklos ;
Lena, Herve ;
Levy, Eric ;
Krzakowski, Maciej ;
Hess, Dagmar ;
Tartour, Eric ;
Chenard, Marie-Pierre ;
Limacher, Jean-Marc ;
Bizouarne, Nadine ;
Acres, Bruce ;
Halluard, Celine ;
Velu, Thierry .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (07) :735-744
[60]  
Ready N, 2006, J CLIN ONCOL, V24, p375S